<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03046979</url>
  </required_header>
  <id_info>
    <org_study_id>AHEAD-HBH002</org_study_id>
    <nct_id>NCT03046979</nct_id>
  </id_info>
  <brief_title>Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)</brief_title>
  <acronym>HCC</acronym>
  <official_title>Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of apatinib in patients with&#xD;
      advanced HCC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. It is&#xD;
      lack of effective drugs for systemic treatment of HCC. Currently, Sorafenib is the only&#xD;
      choice approved by FDA for advanced HCC, although it prolongs the survival for less than 3&#xD;
      months. The treatment of advanced HCC still has a long way to go.&#xD;
&#xD;
      At present, the relevant phase II and phase III clinical studies of apatinib on advanced HCC&#xD;
      are ongoing. Based on our important discovery of our previous clinical studies, we intends to&#xD;
      enlarge the sample size and make further observation for the efficacy and safety of apatinib&#xD;
      in patients with advanced HCC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0[Quality of life]</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety]</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>Apatinib</arm_group_label>
    <other_name>apatinib mesylate tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Before doing any research steps, the patient's informed consent must be obtained&#xD;
             first.&#xD;
&#xD;
          2. The diagnosis of HCC: histologic diagnosis or Alpha fetoprotein (AFP) with two kinds&#xD;
             of imaging diagnosis.&#xD;
&#xD;
          3. Patients of Barcelona stage(BCLC) C with first-line treatment failure or non tolerance&#xD;
             to sorafenib.&#xD;
&#xD;
          4. Ages of 18 to 75 years old.&#xD;
&#xD;
          5. Child-Pugh score between 5-7 points, patients of Child-Pugh 7 points should be without&#xD;
             ascites.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group performance score (ECOG PS) is 0-1 point.&#xD;
&#xD;
          7. Adequate organ function meeting the following:&#xD;
&#xD;
             Hemoglobin(HBG)≧9.0g/dl Neutrophil count(ANC) ≧1,500/mm3 Platelet count(PLT)≧50,000/ul&#xD;
             Total bilirubin (TBIL)&lt; 2mg/dL (3mg/dL, Child-Pugh B) Alanine aminotransferase (ALT)&#xD;
             and Aspartate aminotransferase (AST) &lt; 5×ULN (upper limit of normal) ALP (alkaline&#xD;
             phosphatase ) &lt; 4×ULN PT (prothrombin time) &gt;50% or PT-INR&lt;2.3, &lt;6 seconds or greater&#xD;
             than that of the control&#xD;
&#xD;
          8. For patients taking warfarin, at least once a week to a close monitoring of the&#xD;
             patients, until, according to the standard of treatment, at every time of medication,&#xD;
             the subjects' INR measurements has been stable&#xD;
&#xD;
          9. SCr (serum creatinine) &lt;1.5×ULN&#xD;
&#xD;
         10. For pregnant women, the results of serum pregnancy tests must be negative within 14&#xD;
             days before initiation of treatment.&#xD;
&#xD;
         11. All men and women who participated in the study had to take reliable contraceptive&#xD;
             measures within the trial and two weeks of after the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients of Child-Pugh 7 has serious uncontrolled ascites.&#xD;
&#xD;
          2. Patients with serious cardiovascular disease.&#xD;
&#xD;
          3. Patients with high blood pressure of unable to control.&#xD;
&#xD;
          4. Patients has the history of HIV (human immunodeficiency virus) infection.&#xD;
&#xD;
          5. Active clinical severe infection (&gt; 2, NCI-CTCAE version 3).&#xD;
&#xD;
          6. Need to drug treatment of patients with epilepsy (such as steroid or antiepileptic&#xD;
             drugs)&#xD;
&#xD;
          7. Has a history of allogeneic organ transplantation.&#xD;
&#xD;
          8. Patients with a history of physical signs or have a bleeding.&#xD;
&#xD;
          9. Patients undergoing renal dialysis.&#xD;
&#xD;
         10. Metastatic liver cancer.&#xD;
&#xD;
         11. Patients with uncontrollable ascites.&#xD;
&#xD;
         12. Patients with encephalopathy.&#xD;
&#xD;
         13. Patients has history of gastrointestinal bleeding period of 30 days before join the&#xD;
             study.&#xD;
&#xD;
         14. Patients with a history of esophagus varicosity burst hemorrhage, then not effective&#xD;
             treatment or therapy to prevent recurrence of bleeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ti Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institute &amp; Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ti Zhang, MD</last_name>
    <phone>13920350428</phone>
    <email>zhangti@tjmuch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui-Kai Li, MD</last_name>
    <phone>13820377269</phone>
    <email>tjchlhk@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>TI ZHANG, MD</last_name>
      <phone>+862223340123</phone>
      <phone_ext>3092</phone_ext>
      <email>zhangti@tjmuch.com</email>
    </contact>
    <contact_backup>
      <last_name>Huikai Li, MD</last_name>
      <phone>+862223340123</phone>
      <phone_ext>3091</phone_ext>
      <email>lihuikai@tjmuch.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 16, 2017</study_first_submitted>
  <study_first_submitted_qc>February 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>apatinib</keyword>
  <keyword>advanced hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>the plan to share IPD is under consideration.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

